Among patients with prostate cancer with homologous recombination repair mutations (HRRm) receiving Akeega (niraparib and ...
Rathkopf presented the Late-breaking abstract 91 - Patient-reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled phase 3 trial of niraparib (NIRA) and abiraterone acetate (AA) plus ...
A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...
A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...
This is a preview. Log in through your library . Abstract Homologous recombination is a key process for maintaining genome integrity and diversity. In eukaryotes, the nucleosome structure of chromatin ...
HealthDay on MSN
Drug Combo Effective Against Advanced Prostate Cancer
Niraparib is a “maintenance” drug approved to keep certain types of cancer from coming back, including ovarian cancer, ...
Homologous recombination deficiency (HRD) is a well-described phenotype of some prostate cancers; however, current biomarkers for HRD are imperfect and rely on detection of single gene alterations in ...
Identification of variants influences treatment decisions. Inhibitors of the poly-ADP-ribose polymerase (PARP) system, a pathway for repairing single-stranded DNA breaks, are recommended for tumors ...
Please provide your email address to receive an email when new articles are posted on . Adding niraparib to abiraterone acetate and prednisone lowered risk for cancer growth by 37% among certain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback